Nonclinical precedent Request an invite

Spinraza: genotox, carcinogenicity and repro: done or skipped?

nusinersen · SMN2 (ASO)
Genotoxicity
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)
“ISIS 396443 was negative in an adequately conducted standard battery of in vitro (Ames and chromosomal aberration in CHO) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
Carcinogenicity
Not conducted pre-approval (IT route infeasible); SC carcinogenicity study as postmarketing requirement
“Carcinogenicity studies have not been conducted with nusinersen at this time. The Division has recommended that a carcinogenicity study be conducted after approval.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse fertility/EFD and rabbit EFD (SC): no clear toxicity; PPND ongoing as PMR
“No clear evidence of reproductive or developmental toxicity was seen in mouse and rabbit studies, and ISIS 396443 was negative for genotoxicity in a standard battery of in vitro and in vivo assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Safety pharmacology
Rat IT-infusion respiratory/CV study; CNS endpoints incorporated into monkey IT tox studies
“Safety pharmacology consisted of a respiratory and cardiovascular safety pharmacology study in rats treated by continuous intrathecal (IT) infusion.”
✓ VerifiedFDA pharmacology/toxicology review, p. 71Source ↗
Genotox: Ames
Negative (Ames)
“ISIS 396443 was negative in an adequately conducted standard battery of in vitro (Ames and chromosomal aberration in CHO) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
Genotox: in vitro mammalian
Chromosomal aberration in CHO cells: negative
“ISIS 396443 was negative in an adequately conducted standard battery of in vitro (Ames and chromosomal aberration in CHO) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
Genotox: in vivo
Mouse micronucleus: negative
“ISIS 396443 was negative in an adequately conducted standard battery of in vitro (Ames and chromosomal aberration in CHO) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
Carcinogenicity model
2-year SC mouse study: increased vascular tumors (hemangioma/hemangiosarcoma) at the highest dose
“Administration of nusinersen (0, 5, 15, or 50 mg/kg) to male and female mice by subcutaneous injection, once every two weeks for 2 years, resulted in an increase in the incidence of vascular tumors (combined hemangioma and hemangiosarcoma) at the highest dose tested.”
✓ VerifiedUS prescribing informationSource ↗
Carcinogenicity timing
No carcinogenicity study before approval; 2-year carcinogenicity study is a postmarketing requirement
“the sponsor should conduct a 2-year carcinogenicity study as a post￾marketing requirement.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
hERG / QT
No ECG effects in repeat-dose IT monkey studies; no cardiovascular effects in rats with 25-day IT infusion
“In safety pharmacology studies, there were no pulmonary or cardiovascular effects in rats using continuous intrathecal (IT) infusion for 25 days, or effects on ECG in the repeat-dose IT toxicology studies in monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Amvuttra

vutrisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Conducted: in vitro Ames, CHL chromosomal aberration and in vivo mouse bone marrow micronucleus; no genotoxicity

Defitelio

defibrotide · Fragmented DNA oligonucleotides
Negative: Ames assay and in vivo rat bone marrow micronucleus assay

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Givlaari

givosiran · ALAS1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Hibsago

bepirovirsen · HBV RNA (ASO)
Conducted; negative (Ames, mammalian cell chromosomal aberration, in vivo mouse micronucleus)

Izervay

avacincaptad pegol · C5 (aptamer)
Conducted: Ames, chromosomal aberration in mammalian cells, mouse micronucleus; all negative

Kynamro

mipomersen · APOB (ASO)
Conducted; negative (Ames, mouse lymphoma, mouse micronucleus)

Leqvio

inclisiran · PCSK9 (siRNA)
Conducted: standard panel, negative

Macugen

pegaptanib · VEGF-165 (aptamer)
Conducted (GLP); pegaptanib and 2'-FU/2'-FC nucleosides negative overall

Onpattro

patisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, mouse micronucleus; all negative

Oxlumo

lumasiran · HAO1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Qalsody

tofersen · SOD1 (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Conducted: bacterial reverse mutation, in vitro chromosomal aberration (human lymphocytes), rat bone-marrow micronucleus; all negative

Redemplo

plozasiran · APOC3 (siRNA)
Conducted: Ames, in vitro chromosomal aberration (TK6), in vivo mouse micronucleus; not genotoxic

Rivfloza

nedosiran · LDHA (siRNA)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Rytelo

imetelstat · Telomerase (oligo)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Tegsedi

inotersen · TTR (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Tryngolza

olezarsen · APOC3 (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Viltepso

viltolarsen · DMD exon 53 (PMO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
Conducted: mutagenic potential evaluated in in vitro and in vivo assays

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Wainua

eplontersen · TTR (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Waylivra

volanesorsen · APOC3 (ASO)
Conducted: bacterial reverse mutation, mouse lymphoma TK, mouse bone-marrow micronucleus; all negative

Zanvastro

zilganersen · GFAP (ASO)
Conducted: Ames, in vitro chromosomal aberration, mouse micronucleus; all negative

Summary across all 27 oligonucleotides →